WEBULL
News
INO
1.690
0.00%
0.000
Rosen Law Firm Urges Inovio Pharmaceuticals, Inc. (NASDAQ: INO) Stockholders to Contact the Firm for Information About Their Rights
Barchart · 1d ago
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit
Barchart · 1d ago
Weekly Report: what happened at INO last week (0202-0206)?
Weekly Report · 1d ago
Weekly Report: what happened at INO last week (0126-0130)?
Weekly Report · 02/02 09:51
Inovio Pharmaceuticals Inc. Stock Advances 5.2%, Outperforms Peers
Dow Jones · 01/29 21:35
Inovio Extends Series A Warrants, Enhancing Capital Flexibility
TipRanks · 01/27 21:30
Weekly Report: what happened at INO last week (0119-0123)?
Weekly Report · 01/26 09:51
Inovio Pharmaceuticals Inc. Stock Slips 3.2%, Underperforms Peers
Dow Jones · 01/23 21:35
INO-3107 At The Crossroads: FDA Review Drives Inovio's Upside And Risk
Seeking Alpha · 01/22 10:36
Weekly Report: what happened at INO last week (0112-0116)?
Weekly Report · 01/19 09:55
Inovio Pharmaceuticals Inc. Stock Sheds 3.8%, Underperforms Peers
Dow Jones · 01/16 21:35
Inovio Pharmaceuticals Inc. Stock Sheds 3.7%, Underperforms Peers
Dow Jones · 01/15 21:35
Inovio Pharmaceuticals Inc. Stock Rises 3.9%, Outperforms Market
Dow Jones · 01/13 21:35
Weekly Report: what happened at INO last week (0105-0109)?
Weekly Report · 01/12 09:54
Inovio Pharmaceuticals: Speculative Buy Thesis Hinges On INO-3107
Seeking Alpha · 01/10 14:30
Piper Sandler Reaffirms Their Buy Rating on Inovio Pharmaceuticals (INO)
TipRanks · 01/06 11:35
Inovio Pharmaceuticals Inc. Stock Slides 5.9%, Underperforms Peers
Dow Jones · 01/05 21:34
Weekly Report: what happened at INO last week (1229-0102)?
Weekly Report · 01/05 09:51
Looking Into Inovio Pharmaceuticals Inc's Recent Short Interest
Benzinga · 01/02 14:00
Inovio Pharmaceuticals Inc. Stock Rallies 1.7%, Outperforms Peers
Dow Jones · 12/30/2025 21:35
More
Webull provides a variety of real-time INO stock news. You can receive the latest news about Inovio Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.